KR102413408B1 - 장내 미생물 조성에 영향을 미치는 미생물 카로티노이드 - Google Patents
장내 미생물 조성에 영향을 미치는 미생물 카로티노이드 Download PDFInfo
- Publication number
- KR102413408B1 KR102413408B1 KR1020197001707A KR20197001707A KR102413408B1 KR 102413408 B1 KR102413408 B1 KR 102413408B1 KR 1020197001707 A KR1020197001707 A KR 1020197001707A KR 20197001707 A KR20197001707 A KR 20197001707A KR 102413408 B1 KR102413408 B1 KR 102413408B1
- Authority
- KR
- South Korea
- Prior art keywords
- intestinal
- microbial
- carotenoids
- carotenoid compound
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 235000021466 carotenoid Nutrition 0.000 title claims abstract description 266
- 230000000813 microbial effect Effects 0.000 title claims abstract description 102
- 239000000203 mixture Substances 0.000 title claims abstract description 81
- 244000005709 gut microbiome Species 0.000 title claims description 52
- 150000001747 carotenoids Chemical class 0.000 title abstract description 195
- -1 carotenoid compounds Chemical class 0.000 claims abstract description 80
- 230000000968 intestinal effect Effects 0.000 claims abstract description 58
- 230000007358 intestinal barrier function Effects 0.000 claims abstract description 51
- 238000011282 treatment Methods 0.000 claims abstract description 33
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 26
- 210000005027 intestinal barrier Anatomy 0.000 claims abstract description 26
- 208000002551 irritable bowel syndrome Diseases 0.000 claims abstract description 23
- 230000001771 impaired effect Effects 0.000 claims abstract description 18
- 208000035475 disorder Diseases 0.000 claims abstract description 15
- 230000000694 effects Effects 0.000 claims description 58
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 39
- 230000001580 bacterial effect Effects 0.000 claims description 36
- 241001465754 Metazoa Species 0.000 claims description 31
- 241000894006 Bacteria Species 0.000 claims description 29
- 238000004519 manufacturing process Methods 0.000 claims description 29
- 230000001965 increasing effect Effects 0.000 claims description 25
- 230000002496 gastric effect Effects 0.000 claims description 17
- 230000000770 proinflammatory effect Effects 0.000 claims description 17
- 244000144972 livestock Species 0.000 claims description 15
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 14
- 239000002207 metabolite Substances 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- 241000251468 Actinopterygii Species 0.000 claims description 12
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 12
- 206010012735 Diarrhoea Diseases 0.000 claims description 12
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 12
- 208000015943 Coeliac disease Diseases 0.000 claims description 11
- 208000011231 Crohn disease Diseases 0.000 claims description 11
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- 201000011510 cancer Diseases 0.000 claims description 11
- 241001032451 Bacillus indicus Species 0.000 claims description 10
- 244000052616 bacterial pathogen Species 0.000 claims description 10
- 230000012010 growth Effects 0.000 claims description 10
- 230000035800 maturation Effects 0.000 claims description 10
- 230000036470 plasma concentration Effects 0.000 claims description 10
- 230000009286 beneficial effect Effects 0.000 claims description 9
- 102000004127 Cytokines Human genes 0.000 claims description 8
- 108090000695 Cytokines Proteins 0.000 claims description 8
- 206010011844 Dacryocystitis Diseases 0.000 claims description 8
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 8
- 206010028116 Mucosal inflammation Diseases 0.000 claims description 8
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 8
- 230000002829 reductive effect Effects 0.000 claims description 8
- 241000894007 species Species 0.000 claims description 8
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 7
- 206010010774 Constipation Diseases 0.000 claims description 7
- 201000010927 Mucositis Diseases 0.000 claims description 7
- 208000008589 Obesity Diseases 0.000 claims description 7
- 230000005764 inhibitory process Effects 0.000 claims description 7
- 230000004770 neurodegeneration Effects 0.000 claims description 7
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 7
- 235000020824 obesity Nutrition 0.000 claims description 7
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 6
- 239000000427 antigen Substances 0.000 claims description 6
- 108091007433 antigens Proteins 0.000 claims description 6
- 102000036639 antigens Human genes 0.000 claims description 6
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 6
- 206010012601 diabetes mellitus Diseases 0.000 claims description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 6
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 6
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 6
- 201000005671 spondyloarthropathy Diseases 0.000 claims description 6
- 230000000638 stimulation Effects 0.000 claims description 6
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 6
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims description 5
- 206010022678 Intestinal infections Diseases 0.000 claims description 5
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 5
- 210000004400 mucous membrane Anatomy 0.000 claims description 5
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims description 5
- 208000020016 psychiatric disease Diseases 0.000 claims description 5
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 5
- 230000037147 athletic performance Effects 0.000 claims description 4
- 230000006872 improvement Effects 0.000 claims description 4
- 241000283690 Bos taurus Species 0.000 claims description 3
- 208000027244 Dysbiosis Diseases 0.000 claims description 3
- 241000589323 Methylobacterium Species 0.000 claims description 3
- 241001494479 Pecora Species 0.000 claims description 3
- 241000186547 Sporosarcina Species 0.000 claims description 3
- 241000191940 Staphylococcus Species 0.000 claims description 3
- 241000194017 Streptococcus Species 0.000 claims description 3
- 230000007140 dysbiosis Effects 0.000 claims description 3
- 210000000936 intestine Anatomy 0.000 claims description 3
- 241000272525 Anas platyrhynchos Species 0.000 claims description 2
- 241000272814 Anser sp. Species 0.000 claims description 2
- 241000283707 Capra Species 0.000 claims description 2
- 241000283073 Equus caballus Species 0.000 claims description 2
- 241000287828 Gallus gallus Species 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 2
- 241001400155 Rubritalea Species 0.000 claims description 2
- 241000282898 Sus scrofa Species 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- 150000001875 compounds Chemical class 0.000 abstract description 21
- 239000001751 lycopene Substances 0.000 abstract description 17
- 229960004999 lycopene Drugs 0.000 abstract description 17
- 238000011321 prophylaxis Methods 0.000 abstract description 12
- 210000004027 cell Anatomy 0.000 description 51
- 210000004215 spore Anatomy 0.000 description 35
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 34
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 32
- 241000196324 Embryophyta Species 0.000 description 26
- 241000700159 Rattus Species 0.000 description 24
- 235000005911 diet Nutrition 0.000 description 24
- 230000037213 diet Effects 0.000 description 22
- 210000000813 small intestine Anatomy 0.000 description 21
- 238000002474 experimental method Methods 0.000 description 19
- 239000000284 extract Substances 0.000 description 19
- 235000013734 beta-carotene Nutrition 0.000 description 18
- 239000011648 beta-carotene Substances 0.000 description 18
- 241000282887 Suidae Species 0.000 description 14
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 14
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 14
- 239000000902 placebo Substances 0.000 description 13
- 229940068196 placebo Drugs 0.000 description 13
- 150000004666 short chain fatty acids Chemical class 0.000 description 13
- 230000014509 gene expression Effects 0.000 description 12
- 235000009200 high fat diet Nutrition 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 12
- 210000001072 colon Anatomy 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 235000012680 lutein Nutrition 0.000 description 11
- 239000001656 lutein Substances 0.000 description 11
- 229960005375 lutein Drugs 0.000 description 11
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 11
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 11
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 11
- 241000282412 Homo Species 0.000 description 10
- 241000192125 Firmicutes Species 0.000 description 9
- 206010061218 Inflammation Diseases 0.000 description 9
- 210000004921 distal colon Anatomy 0.000 description 9
- 239000002158 endotoxin Substances 0.000 description 9
- 230000004054 inflammatory process Effects 0.000 description 9
- 229920006008 lipopolysaccharide Polymers 0.000 description 9
- 238000012423 maintenance Methods 0.000 description 9
- 244000005700 microbiome Species 0.000 description 9
- 230000009469 supplementation Effects 0.000 description 9
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 8
- 241000233866 Fungi Species 0.000 description 8
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 8
- 210000004666 bacterial spore Anatomy 0.000 description 8
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 8
- 229960002747 betacarotene Drugs 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 230000036541 health Effects 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 235000004213 low-fat Nutrition 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 7
- 208000023275 Autoimmune disease Diseases 0.000 description 7
- 241000605059 Bacteroidetes Species 0.000 description 7
- 241000193403 Clostridium Species 0.000 description 7
- 230000004888 barrier function Effects 0.000 description 7
- 235000020940 control diet Nutrition 0.000 description 7
- 238000003935 denaturing gradient gel electrophoresis Methods 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 244000052769 pathogen Species 0.000 description 7
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 241000186394 Eubacterium Species 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 230000003078 antioxidant effect Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 230000035699 permeability Effects 0.000 description 6
- 229960003471 retinol Drugs 0.000 description 6
- 235000020944 retinol Nutrition 0.000 description 6
- 239000011607 retinol Substances 0.000 description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 5
- 230000033228 biological regulation Effects 0.000 description 5
- 238000000855 fermentation Methods 0.000 description 5
- 230000004151 fermentation Effects 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- 210000004347 intestinal mucosa Anatomy 0.000 description 5
- 230000003870 intestinal permeability Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- 241001328122 Bacillus clausii Species 0.000 description 4
- 206010033307 Overweight Diseases 0.000 description 4
- 238000011529 RT qPCR Methods 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 230000008827 biological function Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000000112 colonic effect Effects 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 210000002429 large intestine Anatomy 0.000 description 4
- 235000015263 low fat diet Nutrition 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000000693 micelle Substances 0.000 description 4
- 210000003097 mucus Anatomy 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 4
- 208000004998 Abdominal Pain Diseases 0.000 description 3
- 206010000060 Abdominal distension Diseases 0.000 description 3
- 241000203069 Archaea Species 0.000 description 3
- 208000017667 Chronic Disease Diseases 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 3
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 3
- 239000004386 Erythritol Substances 0.000 description 3
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 3
- 102000004125 Interleukin-1alpha Human genes 0.000 description 3
- 108010082786 Interleukin-1alpha Proteins 0.000 description 3
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 3
- 241000186660 Lactobacillus Species 0.000 description 3
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 3
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 239000004376 Sucralose Substances 0.000 description 3
- 102000000591 Tight Junction Proteins Human genes 0.000 description 3
- 108010002321 Tight Junction Proteins Proteins 0.000 description 3
- 108050001370 Tight junction protein ZO-1 Proteins 0.000 description 3
- PFRQBZFETXBLTP-UHFFFAOYSA-N Vitamin K2 Natural products C1=CC=C2C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C(=O)C2=C1 PFRQBZFETXBLTP-UHFFFAOYSA-N 0.000 description 3
- 102000044820 Zonula Occludens-1 Human genes 0.000 description 3
- PNNNRSAQSRJVSB-BXKVDMCESA-N aldehydo-L-rhamnose Chemical compound C[C@H](O)[C@H](O)[C@@H](O)[C@@H](O)C=O PNNNRSAQSRJVSB-BXKVDMCESA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 208000024330 bloating Diseases 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 238000007621 cluster analysis Methods 0.000 description 3
- 238000003501 co-culture Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 235000013325 dietary fiber Nutrition 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 201000006549 dyspepsia Diseases 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 3
- 229940009714 erythritol Drugs 0.000 description 3
- 235000019414 erythritol Nutrition 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 210000003976 gap junction Anatomy 0.000 description 3
- 230000002519 immonomodulatory effect Effects 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000007413 intestinal health Effects 0.000 description 3
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 3
- 229960000511 lactulose Drugs 0.000 description 3
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 235000012661 lycopene Nutrition 0.000 description 3
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 3
- RAKQPZMEYJZGPI-LJWNYQGCSA-N menaquinone-7 Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 RAKQPZMEYJZGPI-LJWNYQGCSA-N 0.000 description 3
- 235000009464 menaquinone-7 Nutrition 0.000 description 3
- 239000011700 menaquinone-7 Substances 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 238000000513 principal component analysis Methods 0.000 description 3
- 230000003595 spectral effect Effects 0.000 description 3
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 3
- 235000019408 sucralose Nutrition 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 210000001578 tight junction Anatomy 0.000 description 3
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- 108010068370 Glutens Proteins 0.000 description 2
- 101001086785 Homo sapiens Occludin Proteins 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 229920002774 Maltodextrin Polymers 0.000 description 2
- 239000005913 Maltodextrin Substances 0.000 description 2
- 208000007101 Muscle Cramp Diseases 0.000 description 2
- 102100032604 Occludin Human genes 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 229940087168 alpha tocopherol Drugs 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 239000003613 bile acid Substances 0.000 description 2
- 239000003833 bile salt Substances 0.000 description 2
- 229940093761 bile salts Drugs 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 206010009887 colitis Diseases 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 230000003436 cytoskeletal effect Effects 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 229920003045 dextran sodium sulfate Polymers 0.000 description 2
- 230000000741 diarrhetic effect Effects 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 102000038379 digestive enzymes Human genes 0.000 description 2
- 108091007734 digestive enzymes Proteins 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001493 electron microscopy Methods 0.000 description 2
- 230000008556 epithelial cell proliferation Effects 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- 210000001723 extracellular space Anatomy 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 235000021050 feed intake Nutrition 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 239000003629 gastrointestinal hormone Substances 0.000 description 2
- 230000035784 germination Effects 0.000 description 2
- 235000021312 gluten Nutrition 0.000 description 2
- 230000002414 glycolytic effect Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000007407 health benefit Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000009263 intestinal permeability test Methods 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 206010025135 lupus erythematosus Diseases 0.000 description 2
- 230000001926 lymphatic effect Effects 0.000 description 2
- 208000002780 macular degeneration Diseases 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 230000003843 mucus production Effects 0.000 description 2
- 230000021332 multicellular organism growth Effects 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 230000031990 negative regulation of inflammatory response Effects 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 230000029553 photosynthesis Effects 0.000 description 2
- 238000010672 photosynthesis Methods 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 238000009372 pisciculture Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 230000009703 regulation of cell differentiation Effects 0.000 description 2
- 230000021014 regulation of cell growth Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 235000021391 short chain fatty acids Nutrition 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229960000984 tocofersolan Drugs 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- 235000004835 α-tocopherol Nutrition 0.000 description 2
- 239000002076 α-tocopherol Substances 0.000 description 2
- 241001156739 Actinobacteria <phylum> Species 0.000 description 1
- 241000186560 Blautia coccoides Species 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 241001112695 Clostridiales Species 0.000 description 1
- 208000019399 Colonic disease Diseases 0.000 description 1
- 102000010970 Connexin Human genes 0.000 description 1
- 108050001175 Connexin Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 208000037487 Endotoxemia Diseases 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010015946 Eye irritation Diseases 0.000 description 1
- 241001608234 Faecalibacterium Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241001453172 Fusobacteria Species 0.000 description 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
- 206010017943 Gastrointestinal conditions Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 231100000416 LDH assay Toxicity 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 102000003940 Occludin Human genes 0.000 description 1
- 108090000304 Occludin Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241000192142 Proteobacteria Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000605947 Roseburia Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 241001261005 Verrucomicrobia Species 0.000 description 1
- 235000021068 Western diet Nutrition 0.000 description 1
- 241001531188 [Eubacterium] rectale Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 230000005549 barrier dysfunction Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 150000004648 butanoic acid derivatives Chemical class 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000001895 carotenoid group Chemical group 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 238000012321 colectomy Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 210000001047 desmosome Anatomy 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000012055 enteric layer Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000008971 epithelial apoptosis Effects 0.000 description 1
- 210000005081 epithelial layer Anatomy 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 231100000013 eye irritation Toxicity 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 230000004136 fatty acid synthesis Effects 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 230000002178 gastroprotective effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 235000004280 healthy diet Nutrition 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000002480 immunoprotective effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 208000003243 intestinal obstruction Diseases 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000002843 lactate dehydrogenase assay Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 238000007857 nested PCR Methods 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000013643 reference control Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000025160 regulation of secretion Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000036964 tight binding Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 230000002100 tumorsuppressive effect Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 235000008939 whole milk Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
- C07H15/10—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical containing unsaturated carbon-to-carbon bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
- A61K2035/115—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Feed For Specific Animals (AREA)
- Fodder In General (AREA)
- Saccharide Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16175832.1 | 2016-06-22 | ||
| EP16175832 | 2016-06-22 | ||
| PCT/EP2017/065348 WO2017220708A1 (en) | 2016-06-22 | 2017-06-22 | Microbial carotenoids affecting gut microbial composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20190039687A KR20190039687A (ko) | 2019-04-15 |
| KR102413408B1 true KR102413408B1 (ko) | 2022-06-27 |
Family
ID=56203217
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020197001707A Active KR102413408B1 (ko) | 2016-06-22 | 2017-06-22 | 장내 미생물 조성에 영향을 미치는 미생물 카로티노이드 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11324717B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3474862B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6966543B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102413408B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN109641006B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2017281589B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112018076485A8 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3028031C (cg-RX-API-DMAC7.html) |
| IL (1) | IL263683B (cg-RX-API-DMAC7.html) |
| MX (1) | MX390386B (cg-RX-API-DMAC7.html) |
| RU (1) | RU2759600C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017220708A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10220089B2 (en) | 2012-08-29 | 2019-03-05 | California Institute Of Technology | Diagnosis and treatment of autism spectrum disorder |
| AU2015339284B2 (en) | 2014-10-30 | 2021-08-05 | California Institute Of Technology | Compositions and methods comprising bacteria for improving behavior in neurodevelopmental disorders |
| US10124025B2 (en) | 2014-10-30 | 2018-11-13 | California Institute Of Technology | Compositions and methods comprising bacteria for improving behavior in neurodevelopmental disorders |
| WO2018148220A1 (en) * | 2017-02-07 | 2018-08-16 | California Institute Of Technology | Modulation of gut microbiota in huntington's disease and rett syndrome |
| EP3720458A4 (en) | 2017-12-05 | 2021-12-08 | BioPlx, Inc. | METHODS AND COMPOSITIONS FOR PREVENTING MICROBIAL INFECTION |
| CN110283754B (zh) * | 2019-07-11 | 2021-02-02 | 中国科学院北京基因组研究所 | 用于类风湿关节炎炎症状态评估及预后评价的肠道微生物菌群 |
| KR102369996B1 (ko) * | 2020-04-21 | 2022-03-02 | 박선민 | 대사성 질환과 안질환의 예방 및 건강 유지를 위한 장내 미생물 검사 기반 맞춤형 프리바이오틱스 또는 프로바이오틱스 정보 제공방법 |
| CN115606802A (zh) * | 2022-10-21 | 2023-01-17 | 中国农业大学 | 番茄红素在制备修复肠屏障损伤的产品中的应用 |
| CN119184223A (zh) * | 2024-10-14 | 2024-12-27 | 元医(杭州)科技有限公司 | 一种基于耐辐射奇球菌素的功能宠物食品及其制备方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007066108A1 (en) * | 2005-12-06 | 2007-06-14 | Royal Holloway And Bedford New College | Bacterial production of carotenoids |
| WO2012017199A1 (en) * | 2010-08-03 | 2012-02-09 | Royal Holloway And Bedford New College Et Al | Fatty acid esters of carotenoid glucosides as colouring agents for foodstuffs |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ560386A (en) * | 2005-01-31 | 2009-12-24 | Mylan Lab Inc | Pharmaceutical composition comprising hydroxylated nebivolol |
-
2017
- 2017-06-22 AU AU2017281589A patent/AU2017281589B2/en active Active
- 2017-06-22 EP EP17732101.5A patent/EP3474862B1/en active Active
- 2017-06-22 WO PCT/EP2017/065348 patent/WO2017220708A1/en not_active Ceased
- 2017-06-22 RU RU2019101481A patent/RU2759600C2/ru active
- 2017-06-22 MX MX2018016118A patent/MX390386B/es unknown
- 2017-06-22 CN CN201780051160.0A patent/CN109641006B/zh active Active
- 2017-06-22 BR BR112018076485A patent/BR112018076485A8/pt not_active Application Discontinuation
- 2017-06-22 US US16/311,431 patent/US11324717B2/en active Active
- 2017-06-22 CA CA3028031A patent/CA3028031C/en active Active
- 2017-06-22 KR KR1020197001707A patent/KR102413408B1/ko active Active
- 2017-06-22 JP JP2019520483A patent/JP6966543B2/ja active Active
-
2018
- 2018-12-12 IL IL263683A patent/IL263683B/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007066108A1 (en) * | 2005-12-06 | 2007-06-14 | Royal Holloway And Bedford New College | Bacterial production of carotenoids |
| WO2012017199A1 (en) * | 2010-08-03 | 2012-02-09 | Royal Holloway And Bedford New College Et Al | Fatty acid esters of carotenoid glucosides as colouring agents for foodstuffs |
Non-Patent Citations (5)
| Title |
|---|
| Charlotte SY et al., Marine Drugs, 2015, vol.13, no.12, 7020-7039쪽 |
| H.A.Hong et al., J. of Applied Microbiology, 2008, vol.105, no.2, 510-520쪽 |
| Kaulmann et al., Nutrition Resarch, 2014, vol.34, no.11, 907-929쪽. |
| Kazutoshi Shindo et al., J. of Antibiotics, 2008, vol.61, no.12, 729-735쪽 |
| Laua Perez-Fons et al., Biochimica et Biophtsica acta, 2010, vol.1811, no.3, 177-185쪽 |
Also Published As
| Publication number | Publication date |
|---|---|
| RU2019101481A (ru) | 2020-07-22 |
| CA3028031C (en) | 2023-02-28 |
| AU2017281589B2 (en) | 2023-03-23 |
| US20190209516A1 (en) | 2019-07-11 |
| CA3028031A1 (en) | 2017-12-28 |
| BR112018076485A2 (pt) | 2019-04-09 |
| IL263683A (en) | 2019-01-31 |
| EP3474862B1 (en) | 2025-10-29 |
| BR112018076485A8 (pt) | 2022-12-06 |
| JP6966543B2 (ja) | 2021-11-17 |
| KR20190039687A (ko) | 2019-04-15 |
| CN109641006B (zh) | 2022-07-01 |
| RU2019101481A3 (cg-RX-API-DMAC7.html) | 2020-10-16 |
| MX390386B (es) | 2025-03-20 |
| RU2759600C2 (ru) | 2021-11-16 |
| CN109641006A (zh) | 2019-04-16 |
| US11324717B2 (en) | 2022-05-10 |
| JP2019524877A (ja) | 2019-09-05 |
| AU2017281589A1 (en) | 2019-01-31 |
| MX2018016118A (es) | 2019-07-08 |
| WO2017220708A1 (en) | 2017-12-28 |
| EP3474862A1 (en) | 2019-05-01 |
| IL263683B (en) | 2022-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102413408B1 (ko) | 장내 미생물 조성에 영향을 미치는 미생물 카로티노이드 | |
| JP6608047B2 (ja) | 多様な機能性を有する新規乳酸菌およびその用途 | |
| JP6954563B2 (ja) | 代謝障害を処置するための低温殺菌アッカーマンシアの使用 | |
| Honda et al. | Anti-diabetic effects of lactic acid bacteria in normal and type 2 diabetic mice | |
| CN102548566B (zh) | 植物乳杆菌菌株用作降血胆固醇试剂 | |
| CN113302279B (zh) | 新乳酸菌及其用途 | |
| Faghfoori et al. | Cellular and molecular mechanisms of probiotics effects on colorectal cancer | |
| KR101807328B1 (ko) | 경구용 ｄｎａ 손상 수복 촉진제 및 엘라스타아제 활성 억제제 | |
| JP6734472B2 (ja) | ラクトバチルス・アシドフィルスを含む更年期の予防または治療用組成物 | |
| KR102084825B1 (ko) | 유아의 과도한 울음용 프로바이오틱 | |
| JP2019524132A (ja) | ラクトバチルス・インテスティナーリスを含む更年期の予防または治療用組成物 | |
| Song et al. | Lactiplantibacillus plantarum DLPT4 protects against cyclophosphamide-induced immunosuppression in mice by regulating immune response and intestinal flora | |
| Han et al. | Postbiotics ameliorate DSS-induced colitis in mice by regulating gut microbiota, promoting tryptophan metabolism, and activating AhR/IL-22 signaling pathway | |
| FR3114106A1 (fr) | Souche bactérienne appartenant au genre Christensenella et compositions | |
| Borgonovi | Biocompostos de buriti e maracujá: perfil, aplicação em leite fermentado probiótico e modulação da microbiota in vitro | |
| Minuto | From youth to old age: therapeutic potential of microbiota interventions in the gut-brain-axis | |
| da FONSECA et al. | The function of nutraceuticals in the intestinal modulation of animals with non-alcoholic steatohepatitis: a systematic review. | |
| Fonseca et al. | Function of nutraceuticals in the intestinal modulation of animals with non-alcoholic steatohepatitis (NASH): a systematic review: a systematic review | |
| AU2023381392A1 (en) | Compositions | |
| McCarville | Effects of prebiotic fibre diets on rat mucosal intestinal and systemic immunity and in vitro mechanistic analysis of anti-inflammatory effects of Lactobacillus strains on rat and human intestinal epithelial cells | |
| Giuliani | Administration of polyphenols-based botanicals: influence of intestinal microbiota’s metabolism, functionality and composition in in vitro simulation technology SHIME®. | |
| Panda | Development of probiotic chocolate from bael | |
| Mtasher et al. | S Research, 10,(11), 75341-75352 | |
| Al-Nabulsi et al. | Health Benefits of Symbiotic Functional Food Products |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20190117 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20200609 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20211029 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20220324 |
|
| PN2301 | Change of applicant |
Patent event date: 20220614 Comment text: Notification of Change of Applicant Patent event code: PN23011R01D |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20220622 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20220622 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration |